New biologic AZD7798 tested in early Crohn's trial
NCT ID NCT05452304
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-stage study tested a new biologic drug called AZD7798 in 112 people, including healthy volunteers and patients with Crohn's disease. The main goal was to check if the drug is safe and how the body processes it. Researchers gave single or repeated doses and monitored for side effects. This is a first step to see if AZD7798 might be a future treatment for Crohn's.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Harrow, HA1 3UJ, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD7798 (a biologic drug given by injection or infusion)
What this could lead to
If successful, this could lead to a new treatment option for Crohn's disease, helping to control inflammation and symptoms.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.